These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 8658683)
1. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. Sugito K; Morozumi K; Oikawa T Transplant Proc; 1996 Jun; 28(3):1335-7. PubMed ID: 8658683 [No Abstract] [Full Text] [Related]
2. A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar? Morozumi K; Sugito K; Oda A; Takeuchi O; Fukuda M; Usami T; Oikawa T; Fujinami T; Koyama K; Takeda A; Yoshida A; Haba T; Tominaga Y; Uchida K; Yokoyama I; Takagi H Transplant Proc; 1996 Apr; 28(2):1076-8. PubMed ID: 8623232 [No Abstract] [Full Text] [Related]
3. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495 [No Abstract] [Full Text] [Related]
4. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233 [No Abstract] [Full Text] [Related]
6. Electron-microscopic peritubular capillary lesion is a specific and useful diagnostic indicator for chronic rejection of renal allografts showing less specific morphologic lesions in the cyclosporine era. Morozumi K; Oikawa T; Fukuda M; Sugito K; Takeuchi O; Usami T; Fujinami T; Yokoyama I; Takagi H; Takeda A; Koyama K; Yoshida A; Haba T; Tominaga Y; Uchida K Transplant Proc; 1997; 29(1-2):89-92. PubMed ID: 9123167 [No Abstract] [Full Text] [Related]
7. Diagnosis of chronic rejection using peritubular and glomerular capillary lesions. Morozumi K; Oikawa T; Fukuda M; Sugito K; Takeuchi O; Oda A; Fujinami T; Takeda A; Uchida K Transplant Proc; 1996 Feb; 28(1):508-11. PubMed ID: 8644331 [No Abstract] [Full Text] [Related]
8. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. Woodle ES; Thistlethwaite JR; Gordon JH Transplant Proc; 1996 Dec; 28(6):3163-4. PubMed ID: 8962225 [No Abstract] [Full Text] [Related]
9. Effect of subclinical rejection on renal allograft histology and function at 6 months. Rush D; Jeffery J; Trpkov K; Solez K; Gough J Transplant Proc; 1996 Feb; 28(1):494-5. PubMed ID: 8644325 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M; Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208 [TBL] [Abstract][Full Text] [Related]
11. Late onset acute rejection of renal allografts, an indicator of suboptimum cyclosporin dosage. Sumethkul V; Jirasiritham S; Chiewsilp P Transplant Proc; 1996 Jun; 28(3):1461-2. PubMed ID: 8658741 [No Abstract] [Full Text] [Related]
12. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Waid T; Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546 [TBL] [Abstract][Full Text] [Related]
13. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). Wilczek HE; Brattström C; Reinholt FP; Tydén G; Ericzon BG Transplant Proc; 1996 Dec; 28(6):3177. PubMed ID: 8962232 [No Abstract] [Full Text] [Related]
14. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors? Nashan B Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616 [TBL] [Abstract][Full Text] [Related]
15. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. Kim HC; Hwang EA; Han SY; Park SB; Kim HT; Cho WH Transplant Proc; 2004 Sep; 36(7):2082-3. PubMed ID: 15518753 [TBL] [Abstract][Full Text] [Related]
16. Effects of and predictors for tacrolimus rescue therapy among renal transplant patients under cyclosporine-based immunosuppression. Hu RH; Lee CY; Tsai MK; Lee PH Transplant Proc; 2004 Sep; 36(7):2092-5. PubMed ID: 15518757 [TBL] [Abstract][Full Text] [Related]
17. Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers. Marchewka Z; Kuźniar J; Zynek-Litwin M; Falkiewicz K; Szymańska B; Roszkowska A; Klinger M Transplant Proc; 2009 Jun; 41(5):1660-5. PubMed ID: 19545703 [TBL] [Abstract][Full Text] [Related]
19. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. Ciancio G; Carreno M; Mathew J; Ricordi C; Garcia R; Karatzas T; Fuller L; Cirocco R; Burke G; Webb M; Nery J; Tzakis A; Roth D; Esquenazi V; Miller J Transplant Proc; 1996 Apr; 28(2):943-4. PubMed ID: 8623473 [No Abstract] [Full Text] [Related]
20. Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group. Transplant Proc; 1993 Feb; 25(1 Pt 1):624-7. PubMed ID: 7679824 [No Abstract] [Full Text] [Related] [Next] [New Search]